Top

Published in:

01-03-2016 | Original Research

Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats

Authors: Yang Liu, Yunfeng Rui, Tin Yan Cheng, Shuo Huang, Liangliang Xu, Fanbiao Meng, Wayne Yuk Wai Lee, Ting Zhang, Nan Li, Chaoyang Li, Huazhu Ke, Gang Li

Published in: Calcified Tissue International | Issue 3/2016

Abstract

The inhibition of sclerostin by the systemic administration of a monoclonal antibody (Scl-Ab) significantly increased bone mass and strength in fractured bones in animal models and non-fractured bones in ovariectomised (OVX) rats. In this study, the effects of Scl-Ab on healing were examined in a closed fracture model in OVX rats. Sixty Sprague-Dawley rats underwent an ovariectomy or a sham operation at 4 months of age, and a closed fracture of the right femur was performed 3 months later. Subcutaneous injections with Scl-Ab (25 mg/kg) or saline were then administered on day 1 after the fracture and twice a week for 8 weeks (n = 20 per group), at which time the fractured femurs were harvested for micro-computed tomography analysis, four-point bending mechanical testing and histomorphometric analysis to examine bone mass, bone strength and dynamic bone formation at the fracture site. The angiogenesis at the fracture site was also examined. Bone marrow stem cells were also isolated from the fractured bone to perform a colony-forming unit (CFU) assay and an alkaline phosphatase-positive (ALP⁺) CFU assay. OVX rats treated with Scl-Ab for 8 weeks had significantly increased bone mineral density and relative bone volume compared with OVX rats treated with saline. Similarly, maximum loading, energy to maximum load and stiffness in Scl-Ab-treated OVX rats were significantly higher than those in saline controls. The mineral apposition rate (MAR), mineralising surface (MS/BS) and bone formation rate (BFR/BS) were also significantly increased in Scl-Ab-treated group compared with the saline-treated group in OVX rats. Furthermore, the Scl-Ab-treated group had more CFUs and ALP⁺ CFUs than the saline-treated group in OVX rats. No significant difference in angiogenesis at the fracture site was found between the groups. Our study demonstrated that Scl-Ab helped to increase bone mass, bone strength and bone formation at the fracture site in a closed femoral fracture model in OVX rats. Bone marrow stem cells in OVX rats injected with Scl-Ab also had increased CFUs and ALP⁺ CFUs.

Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761–1767CrossRefPubMed

Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(Suppl 2):S3–S7CrossRefPubMed

Ke HZ et al (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33(5):747–783CrossRefPubMed

McKibbin B (1978) The biology of fracture healing in long bones. J Bone Joint Surg Br 60-B(2):150–162PubMed

Frost HM (1989) The biology of fracture healing. An overview for clinicians. Part I. Clin Orthop Relat Res 248:283–293PubMed

Li X et al (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24(4):578–588CrossRefPubMed

Ring D et al (2004) Locking compression plates for osteoporotic nonunions of the diaphyseal humerus. Clin Orthop Relat Res 425:50–54CrossRefPubMed

Hill TP et al (2005) Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8(5):727–738CrossRefPubMed

Hoeppner LH, Secreto FJ, Westendorf JJ (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13(4):485–496PubMedCentralCrossRefPubMed

10.

Komatsu DE et al (2010) Modulation of Wnt signaling influences fracture repair. J Orthop Res 28(7):928–936PubMedCentralPubMed

11.

Zhang R et al (2013) Wnt/beta-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 52(1):145–156PubMedCentralCrossRefPubMed

12.

Kamiya N et al (2008) BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135(22):3801–3811PubMedCentralCrossRefPubMed

13.

Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116(5):1202–1209PubMedCentralCrossRefPubMed

14.

Ten Dijke P et al (2008) Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 90(Suppl 1):31–35CrossRefPubMed

15.

Van Bezooijen RL et al (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22(1):19–28CrossRefPubMed

16.

Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577–589PubMedCentralCrossRefPubMed

17.

Balemans W, Ebeling M, Patel N (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10(5):537–543CrossRefPubMed

18.

Kramer I et al (2010) Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25(2):178–189PubMedCentralCrossRefPubMed

19.

McDonald MM et al (2012) Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res 30(10):1541–1548CrossRefPubMed

20.

Padhi D et al (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26(1):19–26CrossRefPubMed

21.

Bonnarens Frank, Einhorn TA (1984) Production of a standard closed fracture in laboratory animal bone. J Orthop Res 2(1):97–102CrossRefPubMed

22.

Mittra E et al (2008) Evaluation of trabecular mechanical and microstructural properties in human calcaneal bone of advanced age using mechanical testing, microCT, and DXA. J Biomech 41(2):368–375CrossRefPubMed

23.

Suen PK et al (2014) Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats. J Orthop Res 32(8):997–1005CrossRefPubMed

24.

Dempster DW et al (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(1):2–17PubMedCentralCrossRefPubMed

25.

He YX et al (2011) Impaired bone healing pattern in mice with ovariectomy-induced osteoporosis: a drill-hole defect model. Bone 48(6):1388–1400CrossRefPubMed

26.

He YX et al (2012) Deletion of estrogen receptor beta accelerates early stage of bone healing in a mouse osteotomy model. Osteoporos Int 23(1):377–389CrossRefPubMed

27.

Xu L et al (2012) Cellular retinol-binding protein 1 (CRBP-1) regulates osteogenenesis and adipogenesis of mesenchymal stem cells through inhibiting RXRalpha-induced beta-catenin degradation. Int J Biochem Cell Biol 44(4):612–619CrossRefPubMed

28.

Augat P et al (2005) Mechanics and mechano-biology of fracture healing in normal and osteoporotic bone. Osteoporos Int 16(Suppl 2):S36–S43CrossRefPubMed

29.

Ominsky MS et al (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26(5):1012–1021CrossRefPubMed

30.

Padhi D, Stouch B, Jang G, Fang L, Darling M, Glise H, Robinson M, Harris S, Posvar E (2007) Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res S1:S37

31.

Hamann C et al (2013) Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 28(3):627–638CrossRefPubMed

32.

Saito M et al (2010) Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone 46(4):1170–1179CrossRefPubMed

33.

Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low trauma fracture in men and women. JAMA 297(4):387–394CrossRefPubMed

34.

Heino TJ, Hentunen TA (2008) Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. Curr Stem Cell Res Ther 3(2):131–145CrossRefPubMed

35.

Farley JR, Baylink DJ (1986) Skeletal alkaline phosphatase activity as a bone formation index in vitro. Metabolism 35(6):563–572CrossRefPubMed

36.

Sutherland MK et al (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35(4):828–835CrossRefPubMed

37.

Winkler DG, Sutherland MK, Geoghegan JC (2003) Osteocyte control of bone formation via sclerostin. EMBO J 22(23):6267–6276PubMedCentralCrossRefPubMed

38.

Jacobsen KA et al (2008) Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res 23(5):596–609PubMedCentralCrossRefPubMed

39.

Street J et al (2002) Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99(15):9656–9661PubMedCentralCrossRefPubMed

40.

Lu C, Marcucio R, Miclau T (2006) Assessing angiogenesis during fracture healing. Iowa Orthop J 26:17–26PubMedCentralPubMed

Title: Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats
Authors: Yang Liu
Yunfeng Rui
Tin Yan Cheng
Shuo Huang
Liangliang Xu
Fanbiao Meng
Wayne Yuk Wai Lee
Ting Zhang
Nan Li
Chaoyang Li
Huazhu Ke
Gang Li
Publication date: 01-03-2016
Publisher: Springer US
Published in: Calcified Tissue International / Issue 3/2016
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-015-0085-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

PTH-Induced Osteoblast Proliferation Requires Upregulation of the Ubiquitin-Specific Peptidase 2 (Usp2) Expression

Point-of-Care Phalangeal Bone Mineral Density Measurement Can Reduce the Need of Dual-Energy X-Ray Absorptiometry Scanning in Danish Women at Risk of Fracture

Bone Structural Changes and Estimated Strength After Gastric Bypass Surgery Evaluated by HR-pQCT

Peroxidase Enzymes Regulate Collagen Biosynthesis and Matrix Mineralization by Cultured Human Osteoblasts

Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands: Combining Claims Data with BMD Measurements

A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page